TABLE I.
Maintenance trials with chemotherapy in non-small-cell lung cancer
| Agent | Reference (study name) | Regimen | Screened (n) | Randomized (n) | pfs (months) | os (months) | |
|---|---|---|---|---|---|---|---|
| Switch maintenance | |||||||
| Vinorelbine | |||||||
| Westeel et al., 200516 (gcot) | mic× 4 → vinorelbine | 573 | 181 | 5 | 12.3 | ||
| mic× 4 → observation | 3 | 12.3 | |||||
| (219 iiib treated with mic × 2 and external-beam rt) | (p=0.32) | (p=0.65) | |||||
| Docetaxel | |||||||
| Fidias et al., 200917 | Cis–gem × 4 → immediate docetaxel | 566 | 309 | 5.7 | 12.3 | ||
| Cis–gem × 4 → delayed docetaxel | 2.7 | 9.7 | |||||
| (p=0.0001) | (p=0.09) | ||||||
| Pemetrexed | |||||||
| Ciuleanu et al., 200918 (jmen) | Platinum doublet × 4 → pemetrexed | nr | 663 (2:1) | 4.3 | 13.4 | ||
| Platinum doublet × 4 → placebo | 2.6 | 10.6 | |||||
| (p<0.0001) | (p=0.01) | ||||||
| Continuation maintenance | |||||||
| Paclitaxel | |||||||
| Belani et al., 200315 | Cb–paclitaxel × 4 → paclitaxel | 401 | 130 | 8.8 | 17.3 | ||
| Cb–paclitaxel × 4 → observation | 6.7 | 13.8 | |||||
| (p=nr) | (p=nr) | ||||||
| Gemcitabine | |||||||
| Brodowicz et al., 200619 | Cis–gem → gem | 354 | 206 (2:1) | 6.6 | 10.2 | ||
| Cis–gem → observation | 5.0 | 8.1 | |||||
| (p<0.001) | (p=0.17) | ||||||
| Belani et al., 201020 | Cb–gem → gem | 519 | 255 | 3.9 | 8.0 | ||
| Cb–gem → observation | 3.8 | 9.3 | |||||
| (p=0.58) | (p=0.84) | ||||||
| Perol et al., 201021 (ifct-gfpc 0502) | Cis–gem → gem | nr | 309 | 3.8 | nr | ||
| Cis–gem → observation | 1.9 | nr | |||||
| Pemetrexed | (p<0.0001) | ||||||
| Paz–Ares et al., 201122 (paramount) | Cis–pemetrexed → pemetrexed | 939 | 539 (2:1) | 3.9 | nr | ||
| Cis–pemetrexed → placebo | 2.6 | nr | |||||
| (p=0.0002) | |||||||
| Barlesi et al., 201123 (avaperl) | cpb → pemetrexed bevacizumab | 376 | 253 | 7.4 | nr | ||
| cpb → bevacizumab | 3.7 | 15.7a | |||||
| (p<0.001) | (p=0.23) | ||||||
a
From the start of first-line therapy in patients randomized to maintenance.
pfs = progression-free survival; os = overall survival; mic = mitomycin–ifosfamide–cisplatin; rt = radiation therapy; Cis = cisplatin; Gem = gemcitabine; nr = not reported; Cb = carboplatin; cpb = cisplatin–pemetrexed–bevacizumab.